Efficacy and Safety Study of Moxidectin in Adults With Scabies

A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults With Scabies.

Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.

Study Overview

• Status: Completed
• Conditions: Scabies
• Intervention / Treatment: Drug: Moxidectin Oral Product; Drug: Moxidectin Oral Product; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 200
• Phase: Phase 2

Contacts and Locations

Study Locations

• Dominican Republic
  • Santo Domingo
    • Santo Domingo Oeste, Santo Domingo, Dominican Republic
      • Instituto Dermatologico Dominicano y Cirugia de Piel
• El Salvador
  • San Salvador, El Salvador, 01101
    • Vargas Clinic
• Honduras
  • Cortes
    • San Pedro Sula, Cortes, Honduras, 21104
      • Hospital y Clinica Bendana
  • Cortez
    • San Pedro Sula, Cortez, Honduras, 21104
      • Derclinic
• United States
  • California
    • Los Angeles, California, United States, 90057
      • La Universal Research Center, Inc
  • Florida
    • Miami, Florida, United States, 33155
      • Advanced Care and Clinical Trials, LLC
    • Miami, Florida, United States, 33016
      • Evolution Clinical Trials
    • Miami, Florida, United States, 33165
      • Medical Research of Westchester, Inc
    • Tampa, Florida, United States, 33612
      • Affinity Clinical Research LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Aged 18 years or older.
2. Provided written informed consent.
3. Diagnosis of active scabies infestation confirmed by the presence of clinical signs and symptoms (evidence of burrows or typical inflammatory/noninflammatory lesions and pruritus) and either microscopic confirmation of scabies mite(s), ova or scybala by skin scraping or dermoscopy.
4. All female subjects of childbearing potential must agree to the use of a highly effective method of birth control until 16 weeks after administration of Investigational Product (IP).

Exclusion Criteria:

1. Diagnosis of crusted/Norwegian scabies or scabies presentation that, in the opinion of the Investigator, would require treatment with more than one standard of care treatment for scabies (e.g., scabies requiring concurrent topical and oral treatment).
2. History of chronic or recurrent dermatologic disease or skin conditions other than scabies that could interfere with the diagnosis of scabies and evaluation of cure.
3. Received any treatment with one or more scabicides within the 28 days prior to Screening, or between Screening and Baseline, including but not limited to permethrin, ivermectin, benzyl benzoate, sulfur, lindane, crotamiton, malathion, tea tree oil or spinosad.
4. Body mass index > 35 kg/m2.
5. Creatinine clearance < 30 mL/min (using Cockcroft-Gault equation).
6. Both total bilirubin >1.5 x upper limit of normal (ULN) and AST > ULN.
7. Abnormal and clinically relevant findings in hematology or biochemistry assessments at Screening, or in vital signs, 12-lead ECG, or physical examination at Screening and/or Baseline, that in the opinion of the Investigator would put the subjects at increased risk from participating in the study, confound study evaluations, or may interfere with study conduct.
8. Presence of any other clinically relevant condition, including infection, immunological disorder, malignant disease, and/or other underlying condition or circumstance at Screening or Baseline that in the opinion of the Investigator would put the subjects at increased risk from participating in the study, confound study evaluations, or interfere with the study conduct.
9. Use of topical steroids, systemic or high-dose inhaled corticosteroids (>500 µg per day of fluticasone propionate or equivalent for adults), or other immunomodulators within 14 days of Baseline.
10. Requiring ongoing treatment with, or received within 5 half-lives before Screening, any of the following medications that are clinical BCRP inhibitors: curcurmin (turmeric) supplements, cyclosporine A, darolutamide, eltrombopag, febuxostat, fostamatinib, rolapitant and teriflunomide.
11. Received an investigational agent within 28 days of Screening (or 5 half-lives of the investigational agent, whichever is longer).
12. Known or suspected hypersensitivity to macrocyclic lactones or excipients used in the formulation of moxidectin or ivermectin.
13. Known or suspected hypersensitivity to any of the components in permethrin 5% cream, to any synthetic pyrethroid or pyrethrin, or to the components of spinosad 0.9% topical suspension.
14. Known, suspected or at risk of Loa loa coinfection.
15. Difficulty swallowing tablets or capsules.
16. Pregnant or breastfeeding or planning to become pregnant from Screening until 16 weeks after treatment with IP.
17. Known or suspected alcohol or illicit substance abuse.
18. Unwilling, unlikely or unable to comply with all protocol specified assessments.
19. Previous enrolment in this study.
20. Previous moxidectin exposure within 6 months (5 half-lives) from Baseline.
21. Has household members who refuse or are unable to receive permethrin 5% cream treatment for scabies.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Moxidectin 8mg; Moxidectin 8 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind.	Drug: Moxidectin Oral Product; The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required; Drug: Moxidectin Oral Product; The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
Experimental: Moxidectin 16mg; Moxidectin 16 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind.	Drug: Moxidectin Oral Product; The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required; Drug: Moxidectin Oral Product; The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
Experimental: Moxidectin 32mg; Moxidectin 32 mg (over encapsulated) will be administered as a single dose on Day 0.	Drug: Moxidectin Oral Product; The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required; Drug: Moxidectin Oral Product; The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
Placebo Comparator: Placebo; 16 Placebo capsules will be administered as a single dose on Day 0.	Drug: Placebo; 16 placebo capsules will be administered as a single dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of Treatment Emergent Adverse Event (Safety)	Incidence and severity of Treatment Emergent Adverse Event (TEAEs), Incidence of serious TEAEs and Incidence of TEAEs leading to study withdrawal and/or death.	84 Days
Proportion of index subjects achieving complete cure (Efficacy)	Proportion of index subjects achieving Complete Cure at Day 28. Complete Cure is defined as demonstration of both: Clinical cure: all signs and symptoms have completely resolved, including burrows, inflammatory/noninflammatory lesions and pruritus. And; Microscopic or dermatoscopic cure demonstrating the absence of mites, eggs, and/or scybala, and negative dermoscopy for burrows.	28 Days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of index subjects achieving clinical cure without microscopic or dermatoscopic cure, assessed by skin examination to confirm all signs of scabies have completely resolved.	The proportion of index subjects demonstrating clinical cure without microscopic or dermatoscopic cure at Day 28.	28 Days
Proportion of index subjects achieving microscopic or dermatoscopic cure without clinical cure. Microscopic or dermatoscopic cure is assessed by demonstrating the absence of scabies mites, eggs, and/or scybala, and negative dermoscopy for burrows.	The proportion of index subjects demonstrating microscopic or dermatoscopic cure without clinical cure at Day 28.	28 Days

Collaborators and Investigators

• Sponsor: Medicines Development for Global Health
• Investigators: Principal Investigator: Richard L Fernandez, MD, Advance Care and Clinical Trials; Principal Investigator: Jorge Lopez, MD, Hospital y Clinica Bendana; Principal Investigator: Daisy Blanco, MD, Instituto Dermatologico Dominicano y Cirugia de Pie; Principal Investigator: Jorge Castillo Molina, MD, Affinity Clinical Research Services; Principal Investigator: Patricia A Zuniga Munoz, MD, Derclinic; Principal Investigator: Laura B Vargas Rivas, MD, Vargas Clinic; Principal Investigator: Gilberto Perez, MD, Evolution Clinical Trials; Principal Investigator: Armando Pineda-Velez, MD, Medical Research of Westchester, Inc; Principal Investigator: Bruce Torkan, MD, La Universal Research Center, Inc

Study record dates

Study Major Dates

• Study Start (Actual): November 23, 2023
• Primary Completion (Actual): November 27, 2024
• Study Completion (Actual): February 11, 2025

Study Registration Dates

• First Submitted: May 16, 2023
• First Submitted That Met QC Criteria: May 16, 2023
• First Posted (Actual): May 25, 2023

Study Record Updates

• Last Update Posted (Actual): May 4, 2025
• Last Update Submitted That Met QC Criteria: May 1, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Keywords: Oral; Moxidectin
• Additional Relevant MeSH Terms: Infections; Parasitic Diseases; Skin Diseases; Skin Diseases, Infectious; Skin Diseases, Parasitic; Mite Infestations; Ectoparasitic Infestations; Scabies; Anti-Infective Agents; Antiparasitic Agents; Antinematodal Agents; Anthelmintics; Moxidectin
• Other Study ID Numbers: MDGH-MOX-2002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No